With 800+ staff members across 21 countries, Synteract is an innovative, full-service contract research organization supporting biopharmaceutical companies in all phases of clinical development to help bring new medicines to market. Synteract has conducted nearly 4,000 studies in 60+ countries, and contributed to more than 240 product approvals. We offer notable expertise in oncology, pediatric, neuro degenerative, rare/orphan, and other indications.
Oncology - In the past 5 years, Synteract has managed 175+ oncology trials, with many in complex treatments like pathway-targeted therapies, chemotherapy, immunotherapy, cell-based and gene therapies. We were the first CRO to begin work in immunotherapy more than 10 years ago.
Pediatrics - We have conducted 95+ pediatric clinical trials globally, in 17 indications. Our pediatric cross-functional team helps clients navigate complex research to allow medicines to serve the littlest ones.
Neuro Degenerative - We have managed 140+ neuro degenerative trials in the last 5 years. Synteract has extensive experience in drugs addressing Alzheimer's, Parkinson's, ALS, MS, migraine, schizophrenia, and more.
Rare & Orphan - We have conducted 100+ trials in rare or orphan diseases in the past 5 years alone. We specialize in unique studies that affect a small portion of the population or are otherwise "forgotten" by other treatments.
Discover how we can support your clinical trials. Visit www.synteract.com or contact us today!